AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Entera Bio 2024 Q2 Earnings Strong EPS Recovery Amid Rising Net Loss
Generated by AI AgentAinvest Earnings Report Digest
Friday, Aug 8, 2025 11:54 pm ET2min read
Aime SummaryEntera Bio (ENTX) reported its fiscal 2024 Q2 earnings on August 8, 2025. The results showed a return to profitability at the EPS level but continued net losses for the company, reflecting mixed performance against a backdrop of ongoing development and regulatory progress.
Entera Bio reported Q2 revenue of $57,000, unchanged year-over-year. The company returned to positive earnings with an EPS of $0.11, reversing from a $0.08 loss in the prior year. However, net losses widened to $4.16 million in the quarter, a 79% increase from the $2.33 million loss in 2023 Q2. The company has now posted losses for three consecutive years in the same quarter, underscoring continued financial challenges.
Revenue
Entera Bio’s revenue remained flat at $57,000 in Q2 2024, the same as in Q2 2023. The company has not yet provided segment-level revenue details, and as such, the full contribution from its drug development pipeline and other initiatives remains unspecified.
Earnings/Net Income
The company returned to profitability at the EPS level with a $0.11 gain, a 237.5% improvement from a $0.08 loss in Q2 2023. However, the net loss expanded significantly to $4.16 million for the quarter, a 79% increase from the prior-year period. Despite the EPS improvement, the company remains unprofitable at the net income level, having recorded losses for three consecutive years in the same quarter.
Price Action
Entera Bio’s stock price has shown a mixed performance in recent periods. Over the last trading day, the stock declined 1.62%. The weekly performance was weaker, with a 6.67% drop, while the month-to-date decline stands at 0.55%. The negative momentum reflects ongoing investor caution.
Post-Earnings Price Action Review
A buy-and-hold strategy initiated following the company’s Q2 2024 earnings report and held for 30 days resulted in zero return over the past three years. This strategy yielded a compound annual growth rate (CAGR) of 0.00% and an excess return of -47.10%, significantly underperforming the 47.10% benchmark return. The strategy also showed a maximum drawdown of 0.00% and volatility of 0.00%, suggesting limited exposure to market risk but a failure to capture broader market gains.
CEO Commentary
Miranda Toledano, Bio’s CEO, highlighted key regulatory advancements for EB613, noting the FDA’s agreement to use Bone Mineral Density (BMD) as the primary endpoint for the Phase 3 trial. This milestone supports the development of the first oral anabolic osteoporosis treatment and reduces the need for additional safety studies. Toledano also emphasized progress in the OPKO collaboration, preclinical developments, and the company’s strengthened balance sheet with $18.9 million in cash. The CEO expressed confidence in executing value-creating milestones through mid-2026.
Guidance
Entera Bio expects the next-generation version of EB613 to enter Phase 1 trials in November 2025. The company also anticipates a Phase 1 study for the OPKO GLP-1/glucagon agonist (OPK-88006), with an IND filing expected in H1 2026. Additionally, Entera aims to present preliminary preclinical PK/PD data for the PTH agonist for hypoparathyroidism by year-end. With $18.9 million in cash and collaboration funding from OPKO, the company expects its financial runway to last through mid-Q3 2026, allowing it to advance multiple programs and meet key development and regulatory milestones.
Additional News
On the Nigerian news front, the Oyo State government has sparked controversy by replacing low-cost stalls at Gbagi Market with more expensive modern alternatives, raising concerns among small traders. Meanwhile, butchers in Lagos have been accused of inflating meat with air to increase weight and deceive customers, a practice that has led to public outrage. Political tensions also remain high, with reports indicating that ex-Abia Deputy Governor Ude Chukwu resigned from the PDP, and the party has expressed indifference to his departure. Additionally, the Nigerian used car market is experiencing a boom as owners sell private vehicles amid rising economic challenges.
Entera Bio reported Q2 revenue of $57,000, unchanged year-over-year. The company returned to positive earnings with an EPS of $0.11, reversing from a $0.08 loss in the prior year. However, net losses widened to $4.16 million in the quarter, a 79% increase from the $2.33 million loss in 2023 Q2. The company has now posted losses for three consecutive years in the same quarter, underscoring continued financial challenges.
Revenue
Entera Bio’s revenue remained flat at $57,000 in Q2 2024, the same as in Q2 2023. The company has not yet provided segment-level revenue details, and as such, the full contribution from its drug development pipeline and other initiatives remains unspecified.
Earnings/Net Income
The company returned to profitability at the EPS level with a $0.11 gain, a 237.5% improvement from a $0.08 loss in Q2 2023. However, the net loss expanded significantly to $4.16 million for the quarter, a 79% increase from the prior-year period. Despite the EPS improvement, the company remains unprofitable at the net income level, having recorded losses for three consecutive years in the same quarter.
Price Action
Entera Bio’s stock price has shown a mixed performance in recent periods. Over the last trading day, the stock declined 1.62%. The weekly performance was weaker, with a 6.67% drop, while the month-to-date decline stands at 0.55%. The negative momentum reflects ongoing investor caution.
Post-Earnings Price Action Review
A buy-and-hold strategy initiated following the company’s Q2 2024 earnings report and held for 30 days resulted in zero return over the past three years. This strategy yielded a compound annual growth rate (CAGR) of 0.00% and an excess return of -47.10%, significantly underperforming the 47.10% benchmark return. The strategy also showed a maximum drawdown of 0.00% and volatility of 0.00%, suggesting limited exposure to market risk but a failure to capture broader market gains.
CEO Commentary
Miranda Toledano, Bio’s CEO, highlighted key regulatory advancements for EB613, noting the FDA’s agreement to use Bone Mineral Density (BMD) as the primary endpoint for the Phase 3 trial. This milestone supports the development of the first oral anabolic osteoporosis treatment and reduces the need for additional safety studies. Toledano also emphasized progress in the OPKO collaboration, preclinical developments, and the company’s strengthened balance sheet with $18.9 million in cash. The CEO expressed confidence in executing value-creating milestones through mid-2026.
Guidance
Entera Bio expects the next-generation version of EB613 to enter Phase 1 trials in November 2025. The company also anticipates a Phase 1 study for the OPKO GLP-1/glucagon agonist (OPK-88006), with an IND filing expected in H1 2026. Additionally, Entera aims to present preliminary preclinical PK/PD data for the PTH agonist for hypoparathyroidism by year-end. With $18.9 million in cash and collaboration funding from OPKO, the company expects its financial runway to last through mid-Q3 2026, allowing it to advance multiple programs and meet key development and regulatory milestones.
Additional News
On the Nigerian news front, the Oyo State government has sparked controversy by replacing low-cost stalls at Gbagi Market with more expensive modern alternatives, raising concerns among small traders. Meanwhile, butchers in Lagos have been accused of inflating meat with air to increase weight and deceive customers, a practice that has led to public outrage. Political tensions also remain high, with reports indicating that ex-Abia Deputy Governor Ude Chukwu resigned from the PDP, and the party has expressed indifference to his departure. Additionally, the Nigerian used car market is experiencing a boom as owners sell private vehicles amid rising economic challenges.
Ainvest Earnings Report Digest
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Limoneira 2025 Q4 Earnings Widens Loss by 369% as Q4 Earnings Miss Expectations
Dec.23 2025
Electrovaya 2025 Q4 Earnings Record Net Income Surges 1896.5% from Loss
Dec.20 2025
Winnebago Industries 2026 Q1 Earnings Record Revenue and 205.8% Net Income Turnaround
Dec.19 2025
Paychex 2026 Q2 Earnings Beats Revenue Estimates, EPS Falls Short
Dec.19 2025
Lamb Weston Holdings 2026 Q2 Earnings 272% Net Income Surge and 1.1% Revenue Growth
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet